Showing results (111-120 of 139) with videos related to
Sort By:
Pageof 14
Journal of Health Care for the Poor and Underserved|February 23, 2010
Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumoniaJorge P Parada, Paul R Yarnold, Constance R Uphold, et al.Medical Care|October 25, 2007
Developing indicators of inpatient adverse drug events through nonlinear analysis using administrative dataJonathan R Nebeker, Paul R Yarnold, Robert C Soltysik, et al.Drug Safety|April 6, 2007
Systematic review of piperacillin-induced neutropeniaMarc H Scheetz, June M McKoy, Jorge P Parada, et al.Medical Care|December 1, 2007
Development and validation of a short-form, rapid estimate of adult literacy in medicineAhsan M Arozullah, Paul R Yarnold, Charles L Bennett, et al.Drug Safety|February 25, 2009
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) projectJune M McKoy, Charles L Bennett, Marc H Scheetz, et al.Stroke|January 7, 2004
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug AdministrationAnaadriana Zakarija, Nicholas Bandarenko, Dilip K Pandey, et al.International Journal of Cancer|February 11, 2020
End of an era for erythropoiesis-stimulating agents in oncologyMartin W Schoen, Shamia Hoque, Bartlett J Witherspoon, et al.Journal of Oncology Practice|May 16, 2017
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced AnemiaVirginia Noxon, Kevin B Knopf, LeAnn B Norris, et al.Cancer Medicine|June 22, 2017
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Rachel A Sabol, Virginia Noxon, Oliver Sartor, et al.The Lancet. Oncology|December 3, 2020
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse ReactionsCharles L Bennett, Martin W Schoen, Shamia Hoque, et al.Pageof 14